206 related articles for article (PubMed ID: 22424863)
1. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
2. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.
Ewing GP; Goff LW
Clin Colorectal Cancer; 2010 Oct; 9(4):219-23. PubMed ID: 20920993
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.
Sachdev D; Yee D
J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):27-39. PubMed ID: 16947084
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
7. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
Hofmann F; García-Echeverría C
Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
[TBL] [Abstract][Full Text] [Related]
8. Targeting IGF-1R in the treatment of sarcomas: past, present and future.
Kim SY; Wan X; Helman LJ
Bull Cancer; 2009; 96(7):E52-60. PubMed ID: 19617179
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
10. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
13. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics.
Christopoulos PF; Corthay A; Koutsilieris M
Cancer Treat Rev; 2018 Feb; 63():79-95. PubMed ID: 29253837
[TBL] [Abstract][Full Text] [Related]
14. New agents in development for breast cancer.
Gao XP; Liu F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
[TBL] [Abstract][Full Text] [Related]
15. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
16. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
Gao J; Chang YS; Jallal B; Viner J
Cancer Res; 2012 Jan; 72(1):3-12. PubMed ID: 22215692
[TBL] [Abstract][Full Text] [Related]
17. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
Wu J; Zhu AX
J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
[TBL] [Abstract][Full Text] [Related]
18. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M
Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410
[TBL] [Abstract][Full Text] [Related]
19. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
